These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 174041)

  • 1. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
    Van Amburg AL; Presant CA; Vélez-García E; Klahr C
    Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
    Wilson WL; Andrews NC; Frelick RW; Nealon TF; Bick RL; Adams T
    Cancer Treat Rep; 1976 Mar; 60(3):269-71. PubMed ID: 816467
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of dibromodulcitol (NSC-104800).
    Andrews NC; Weiss AJ; Wilson W; Nealon T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):653-60. PubMed ID: 4426045
    [No Abstract]   [Full Text] [Related]  

  • 5. Hexamethylmelamine as a single agent in the treatment of small-cell carcinoma of the lung.
    Goldsweig HG; Edgerton F; Redden CS; Takita H; Garza JG; Bisel HF
    Am J Clin Oncol; 1982 Jun; 5(3):267-72. PubMed ID: 6282109
    [No Abstract]   [Full Text] [Related]  

  • 6. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
    Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
    Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
    Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
    DiBella NJ; Nelson RA; Norgard MJ
    Oncology; 1975; 32(2):82-5. PubMed ID: 815858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
    Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
    Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
    Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
    Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Stolinsky DC; Bull FE; Pajak TF; Bateman JR
    Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Mercaptopurine (NSC-755) given intermittently in high doses: phase II study.
    Fink DJ; Foye LV
    Cancer Chemother Rep; 1970 Feb; 54(1):31-4. PubMed ID: 4945996
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK; Thurman WG; Isaacs BL; Talley RW
    Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
    Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
    Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
    Huang MN; Takita H; Catane H; Yee Chen T
    Oncology; 1978; 35(1):29-32. PubMed ID: 203884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexamethylmelamine in advanced head and neck cancer. A phase II study.
    Gad-El-Mawla N; Macdonald JS; Khaled H
    Am J Clin Oncol; 1984 Jun; 7(3):205-8. PubMed ID: 6428214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
    Drelichman A; Brownlee R; Al-Sarraf M
    Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
    Haas CD; Baker L; Thigpen T
    Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
    Weiss AJ; Wilson WL
    Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II evaluation of aclacinomycin-A in patients with adenocarcinoma and large cell carcinoma of the lung.
    Tapazoglou E; Haas CD; Samson MK; Baker LH; Pazdur R
    Am J Clin Oncol; 1985 Aug; 8(4):298-301. PubMed ID: 3002165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.